Genotype is an important determinant of phenotype in adenosine deaminase deficiency

被引:72
作者
Hershfield, MS [1 ]
机构
[1] Duke Univ, Med Ctr, Durham, NC 27710 USA
关键词
D O I
10.1016/S0952-7915(03)00104-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Adenosine deaminase (ADA) deficiency is associated with a broad clinical and mutational spectrum. Defining the relationship of genotype to phenotype among patients with different degrees of immunodeficiency has been complicated because the disease is rare, most mutations are 'private' and patients are often heteroallelic. In recent years, knowledge of ADA structure and systematic expression of mutant alleles have revealed that phenotype is strongly associated with the sum of ADA activity provided by both alleles. A scale for ranking novel ADA alleles based on expression may have utility if newborn screening for primary immunodeficiency disorders is initiated.
引用
收藏
页码:571 / 577
页数:7
相关论文
共 50 条
[1]  
Apasov S, 2000, BLOOD, V95, P3859
[2]   Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling [J].
Apasov, SG ;
Blackburn, MR ;
Kellems, RE ;
Smith, PT ;
Sitkovsky, MV .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (01) :131-141
[3]   T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation [J].
Ariga, T ;
Oda, N ;
Yamaguchi, K ;
Kawamura, N ;
Kikuta, H ;
Taniuchi, S ;
Kobayashi, Y ;
Terada, K ;
Ikeda, H ;
Hershfield, MS ;
Kobayashi, K ;
Sakiyama, Y .
BLOOD, 2001, 97 (09) :2896-2899
[4]   Molecular basis for paradoxical carriers of adenosine deaminase (ADA) deficiency that show extremely low levels of ADA activity in peripheral blood cells without immunodeficiency [J].
Ariga, T ;
Oda, N ;
Sanstisteban, I ;
Arrendondo-Vega, FX ;
Shioda, M ;
Ueno, H ;
Terada, K ;
Kobayashi, K ;
Hershfield, MS ;
Sakiyama, Y .
JOURNAL OF IMMUNOLOGY, 2001, 166 (03) :1698-1702
[5]   Adenosine deaminase deficiency: Genotype-phenotype correlations based on expressed activity of 29 mutant alleles [J].
Arredondo-Vega, FX ;
Santisteban, I ;
Daniels, S ;
Toutain, S ;
Hershfield, MS .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 63 (04) :1049-1059
[6]   Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy [J].
Arredondo-Vega, FX ;
Santisteban, I ;
Richard, E ;
Bali, P ;
Koleilat, M ;
Loubser, M ;
Al-Ghonaium, A ;
Al-Helali, M ;
Hershfield, MS .
BLOOD, 2002, 99 (03) :1005-1013
[7]  
ARREDONDOVEGA FX, 1994, AM J HUM GENET, V54, P820
[8]  
BENVENISTE P, 1995, J IMMUNOL, V155, P536
[9]   P53 EXPRESSION IS REQUIRED FOR THYMOCYTE APOPTOSIS INDUCED BY ADENOSINE-DEAMINASE DEFICIENCY [J].
BENVENISTE, P ;
COHEN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (18) :8373-8377
[10]   The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice - Differential impact on pulmonary and immunologic abnormalities [J].
Blackburn, MR ;
Aldrich, M ;
Volmer, JB ;
Chen, W ;
Zhong, HY ;
Kelly, S ;
Hershfield, MS ;
Datta, SK ;
Kellems, RE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (41) :32114-32121